Patient Case Studies

Patient Case Studies

KEYTRUDA® (pembrolizumab) Prescribing Information for Great Britain & Northern Ireland [External links]

KISPLYX® (lenvatinib) Prescribing information for Great Britain & Northern Ireland [External link]

Welcome to the advanced RCC KEYLearning Hub, learn from your oncology peer in the below advanced renal cell carcinoma (aRCC) case study, treating a patient with KEYTRUDA in combination with KISPLYX.

KEYTRUDA, in combination with KISPLYX, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.¹

Please refer to the individual product SmPCs before prescribing.

Case study summary

Dr Ricky Frazer, Consultant Medical Oncologist at the Velindre Cancer Centre in Cardiff presents a case study of a 57 year old male with advanced renal cell carcinoma, treated with KEYTRUDA in combination with KISPLYX. This patient was diagnosed with multiple metastases (lung mets and large bone mets) and was classified as IMDC intermediate risk.

Dr Ricky Frazer, describes his treatment decision making, management of adverse events and the patient’s treatment outcome.

This content is intended to be viewed on laptop/desktop only, for optimal view please watch the video in full-screen using the button in the bottom right.

KEYTRUDA® (pembrolizumab) Prescribing Information for Great Britain & Northern Ireland [External links]

KISPLYX® (lenvatinib) Prescribing information for Great Britain & Northern Ireland [External link]

Filmed: May 2023 | Length: 10:30

Reference

1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

KEYTRUDA Prescribing Information for Great Britain & Northern Ireland

KISPLYX Prescribing information for Great Britain & Northern Ireland

By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website